Tudor Investment Corp ET AL Acquires Shares of 33,332 LivaNova PLC

Hedge fund increases stake in medical technology company

Mar. 29, 2026 at 11:12am

Got story updates? Submit your updates here. ›

Tudor Investment Corp ET AL, a prominent hedge fund, has acquired a new stake of 33,332 shares in LivaNova PLC (NASDAQ:LIVN), a global medical technology company focused on cardiac surgery and neuromodulation therapies. The transaction, valued at approximately $1.75 million, represents 0.06% ownership of LivaNova.

Why it matters

This investment by Tudor Investment Corp ET AL, a respected hedge fund, signals confidence in LivaNova's growth potential and the firm's belief in the company's long-term prospects within the medical technology industry. The acquisition also highlights the continued interest from institutional investors in the cardiac and neuromodulation device markets.

The details

According to a recent filing with the Securities and Exchange Commission, Tudor Investment Corp ET AL purchased 33,332 shares of LivaNova PLC during the third quarter. This new stake represents approximately 0.06% of the company's outstanding shares. LivaNova is a global medical technology firm that develops and manufactures products and therapies for cardiac surgery and neuromodulation markets, serving hospitals and clinics in over 100 countries.

  • The transaction occurred during the third quarter of the fiscal year.

The players

Tudor Investment Corp ET AL

A prominent hedge fund that has acquired a new stake in LivaNova PLC.

LivaNova PLC

A global medical technology company focused on cardiac surgery and neuromodulation therapies, headquartered in London, United Kingdom and Houston, Texas.

Got photos? Submit your photos here. ›

The takeaway

This investment by Tudor Investment Corp ET AL underscores the continued institutional interest in the medical technology sector, particularly in companies like LivaNova that are developing innovative cardiac and neuromodulation solutions. The acquisition signals the hedge fund's confidence in LivaNova's growth potential and long-term prospects within the industry.